News|Articles|April 4, 2024

Pharma Pulse 4/4/24: Patient Adherence Tools Improve the Patient Journey, ‘Carefluencers’ & more

The latest news for pharma industry insiders.

The Power of Patient Adherence Tools to Improve the Patient Journey

Why manufacturers should leverage technology to address low adherence rates.

Data Analytics Help Specialty Pharmacies Personalize Health Care

Advanced analytics will continue to make health care more accessible and empower pharmacists with the ability to personalize treatments.

‘Carefluencers’ Are Helping Older Loved Ones, and Posting About It

On TikTok and Instagram, people are sharing what it’s like to take care of relatives who have reached their final years.

Johnson & Johnson Expands Commitment to Advance Health Equity

Johnson & Johnson supports more than 100 community-led organizations in marginalized communities to provide resources and tools to advance accessible, quality health care in the US

@US_FDA on X:

It’s National Public Health Week—a week to celebrate and raise awareness of public health. Learn more about women's health topics from the FDA Office of Women's Health!

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.